Edwyn
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $238,228 | $263,966 | $276,711 | $308,951 | $359,051 |
| Gross Profit | $12,148 | $13,130 | $12,358 | $12,828 | $13,323 |
| Operating Income | -$5,040 | $2,038 | $4,381 | $3,909 | $4,422 |
| Net Income | -$4,539 | $1,114 | $3,560 | $3,002 | $3,295 |
Over the past five years, McKESSON CORPORATION has demonstrated a marked recovery and growth trajectory. In 2021, the company reported revenue of approximately USD 238.2 billion alongside a negative operating income of USD 5.04 billion and net income of USD 4.54 billion, signaling significant operational challenges. However, by 2022, revenue had grown to about USD 264.0 billion and the company reversed its fortunes by recording an operating income of USD 2.04 billion and net income of USD 1.11 billion—a dramatic turnaround representing an improvement of over 200% in operating income compared to the previous year. Despite modest fluctuations in gross profit figures (ranging from roughly USD 12.1 billion to USD 13.3 billion), the shift from losses to profits highlights effective cost control and operational restructuring. From 2023 through 2025, revenues continued on an upward trend—from USD 276.7 billion in 2023 to an impressive USD 359.1 billion in 2025—indicating robust top-line growth. Operating income peaked at USD 4.38 billion in 2023, experienced a slight dip to USD 3.91 billion in 2024, and recovered to USD 4.42 billion in 2025. Net income followed a similar pattern, peaking at USD 3.56 billion in 2023 before a modest decline in 2024 and a subsequent increase in 2025. These fluctuations, while notable, are within a range that suggests operational adjustments rather than systemic issues. Given McKESSON’s role in healthcare distribution—an industry characterized by cyclical demand and regulatory complexity—the company’s steady revenue growth coupled with its turnaround from a loss position suggests improving financial health and sustainable operational performance moving forward.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.